1. Jazz Pharmaceuticals. Defitelio (defibrotide sodium) Prescribing Information. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208114lbl.pdf.
2. Tocchetti P, Tudone E, Marier J-F, Marbury T, Zomorodi K, Eller M. Pharmacokinetic profile of defibrotide in patients with renal impairment. Drug Des Dev Ther. 2016;ume 10:2631–41.
3. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with def ibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44.